CETP Genotypes and Cardiovascular Risk

Results of a large systematic review suggest that the CETP pathway may yet prove a worthwhile target for preventive intervention.

Although findings from recent studies of torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, have demonstrated increased mortality and little impact on coronary atherosclerosis (JW Cardiol Nov 5 2007), other CETP inhibitors are in development. To inform future research efforts in this area, investigators conducted a comprehensive review of 102 studies (encompassing more than 147,000 subjects) exploring the associations of CETP genotypes with CETP functionality, lipoprotein cholesterol levels, and coronary heart disease risk. They focused on six CETP genotypes: TaqIB, I405V, –629C>A, D442G, –631C>A, and R451Q.

Overall, CETP variants were common; minor alleles were found in about half of the study population. Individuals with t…

Reviewing Author

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)

CETP Genotypes and Cardiovascular Risk

Topics

Reviewing Author